摘要
目的探讨RhoA在卵巢癌组织中的表达及其临床意义。方法用免疫组织化学S-P法检测63例卵巢癌患者、17例卵巢良性肿瘤患者和9例正常对照者卵巢组织中RhoA蛋白的表达。结果卵巢癌患者中RhoA阳性率为76.2%,其中强阳性11例(17.5%),明显高于正常对照组和卵巢良性肿瘤组(P<0.01);高分化、中分化和低分化卵巢癌患者RhoA阳性率依次为76.9%、77.8%和66.7%,差异无统计学意义(P>0.05);Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期卵巢癌患者RhoA阳性率依次为69.0%、76.5%、83.3%和100.0%,差异有统计学意义(P<0.05)。结论卵巢癌患者RhoA表达水平高于正常人,其可能参与卵巢癌的发生发展,可作为卵巢癌的临床诊断及预后评估提供有价值的参考。
Objective To study on the expression of RhoA in ovarian cancer tissue and its clinical significance.Methods By immunohistochemistry（S-P）,the expression of RhoA was detected in 63 ovarian cancer patients,17 ovaries benign tumor patients and 9 health volunteers and evaluated for its clinical significance.Results The positive rates of RhoA in ovaries tissue in patients with ovarian cancer is obviously higher than those in control group and benign tumor（P〈0.01）.The positive rates of RhoA were 76.9%,77.8% and 66.7% in well,moderately and poorly differentiated cancer with significant difference（P〈0.05）.The positive rates of RhoA were 69.0%,76.5%,83.3% and 100.0% in Ⅰ,Ⅱ,Ⅲ and Ⅳ stage with statistical difference（P〈0.05）.Conclusion The expression of RhoA is higher in patients with ovarian cancer than that in normal control group,which should take part in ovarian cancer and could provide scientific evidence for clinical diagnosis and prognosis.
出处
《医学综述》
2008年第11期1738-1740,共3页
Medical Recapitulate
关键词
卵巢癌
RHOA
免疫组织化学
Ovarian cancer
Ras homolog gene family,member A
Immunohistochemistry
